Circulating estrone levels are associated prospectively with diabetes risk in men of the framingham heart study

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2591-2596

  Jasuja, Guneet Kaur ^a,b   Travison, Thomas G ^c,d   Davda, Maithili ^c   Rose, Adam J ^b,c   Zhang, Anqi ^c   Kushnir, Mark M ^e   Rockwood, Alan L ^e   Meikle, Wayne ^e   Coviello, Andrea D ^c   D'Agostino, Ralph ^a,b   Vasan, Ramachandran S ^c,f   Bhasin, Shalender ^c  

^a Boston University   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e ARUP LABORATORIES   (United States)

^f FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRONE; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMMUNITY LIVING; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; INCIDENTAL FINDING; LIQUID CHROMATOGRAPHY; LONGITUDINAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 84888112697     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2477     Document Type: Article

References (34)

1. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003;284:E7-E12
2. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132: 895-901
3. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middleaged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23: 490-494
4. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone- binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27: 1036-1041
5. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002;25: 55-60
6. Sargeant LA, Wareham NJ, Khaw KT. Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: a populationbased study. Diabetes Metab Res Rev 2000; 16: 20-25
7. Nabulsi AA, Folsom AR, White A, et al.; The Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328: 1069-1075
8. Kanaya AM, Herrington D, Vittinghoff E, et al.; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138: 1-9
9. Howard BV, Margolis KL, Allen C, et al. The influence of postmenopausal estrogen/ progestin therapy on glucose and insulin concentrations and the risk of diabetes in postmenopausal women: the Women's Health Initiative (Abstract). Diabetes 2003; 52(Suppl. 1):A142
10. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/ Progestin Interventions. Diabetes Care 1998;21: 1589-1595
11. Manrique C, Lastra G, Habibi J, Mugerfeld I, Garro M, Sowers Jr. Loss of estrogen receptor a signaling leads to insulin resistance and obesity in young and adult female mice. Cardiorenal Med 2012;2: 200-210
12. Vikan T, Schirmer H, Njølstad I, Svartberg J. Low testosterone and sex hormonebinding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol 2010; 162: 747-754
13. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-1299
14. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23: 912-918
15. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. Steroids 2003;68: 1173-1178
16. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3791-3797
17. Bhasin S, Zhang A, Coviello A, et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008;73: 1311-1317
18. Wartofsky L, Handelsman DJ. Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab 2010; 95: 5141-5143
19. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951;41: 279-281
20. Ingelsson E, Massaro JM, Sutherland P, et al. Contemporary trends in dyslipidemia in the FraminghamHeart Study. Arch Intern Med 2009;169: 279-286
21. Kushnir MM, Rockwood AL, Bergquist J, et al. High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol 2008;129: 530-539
22. Jasuja GK, Travison TG, Davda M, et al. Age trends in estradiol and estrone levels measured using liquid chromatography tandem mass spectrometry in communitydwelling men of the Framingham Heart Study. J Gerontol A Med Sci. 25 October 2012 [Epub ahead of print]
23. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. Steroids 2009;74: 512-519
24. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a communitybased sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96: 2430-2439
25. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159: 702-706
26. Barrett-Connor E, Ensrud KE, Harper K, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003;25: 919-930
27. Andersson B, Johannsson G, Holm G, et al. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 2002;87: 122-128
28. Lipscombe LL, Fischer HD, Yun L, et al. Association between tamoxifen treatment and diabetes: a population-based study. Cancer 2012;118: 2615-2622
29. Xu Y, Nedungadi TP, Zhu L, et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab 2011;14: 453-465
30. Barros RP, Gustafsson JÅ. Estrogen receptors and the metabolic network. Cell Metab 2011;14: 289-299
31. Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol 2010;122: 74-81
32. Nagamani M, Szymajda A, Sepilian V, Urban RJ, Gilkison C. Effects of raloxifene on insulin sensitivity, b-cell function, and hepatic insulin extraction in normal postmenopausal women. Fertil Steril 2008;89: 614-619
33. Genuth S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26: 3160-3167
34. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva, World Health Organization, 2006